A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2

DOI: 10.4143/crt.2018.387

Keywords: Osimertinib, T790M, Circulating tumor DNA, Non-small cell lung carcinoma

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text